HOOKIPA Pharma (HOOKIPA Pharma) Forward Dividend Yield % : 0.00% (As of May. 18, 2024)

View and export this data going back to 2019. Start your Free Trial

What is HOOKIPA Pharma Forward Dividend Yield %?

As of today (2024-05-18), the Forward Annual Dividend Yield of HOOKIPA Pharma is 0.00%.

As of today (2024-05-18), the Trailing Annual Dividend Yield of HOOKIPA Pharma is 0.00%.

HOOK's Forward Dividend Yield % is not ranked ^*
in the Biotechnology industry.
Industry Median: 1.56
* Ranked among companies with meaningful Forward Dividend Yield % only.

HOOKIPA Pharma's Dividends per Share for the three months ended in Mar. 2024 was $0.00.

The growth rate is calculated with least square regression.

For more information regarding to dividend, please check our Dividend Page.

Competitive Comparison of HOOKIPA Pharma's Forward Dividend Yield %

For the Biotechnology subindustry, HOOKIPA Pharma's Forward Dividend Yield %, along with its competitors' market caps and Forward Dividend Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

HOOKIPA Pharma's Forward Dividend Yield % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, HOOKIPA Pharma's Forward Dividend Yield % distribution charts can be found below:

* The bar in red indicates where HOOKIPA Pharma's Forward Dividend Yield % falls into.

HOOKIPA Pharma Forward Dividend Yield % Calculation

Dividend Yield measures how much a company pays out in dividends each year relative to its share price.

HOOKIPA Pharma (NAS:HOOK) Forward Dividend Yield % Explanation

Over the long term, the return from dividends has been a significant contributor to the total returns produced by equity securities. Studies by Elroy Dimson, Paul Marsh, and Mike Staunton of Princeton University (2002) found that a market-oriented portfolio, which included reinvested dividends, would have generated nearly 85 times the wealth generated by the same portfolio relying solely on capital gains.

Dividends may also qualify a lower tax rate for investors.

In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.

You can find the stocks that owned most by Gurus here. Or you can check out Warren Buffett's highest dividend stocks here.

HOOKIPA Pharma Forward Dividend Yield % Related Terms

Thank you for viewing the detailed overview of HOOKIPA Pharma's Forward Dividend Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.

HOOKIPA Pharma (HOOKIPA Pharma) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » HOOKIPA Pharma Inc (NAS:HOOK) » Definitions » Forward Dividend Yield %

Comparable Companies

Traded in Other Exchanges

N/A

Address

350 Fifth Avenue, 72nd Floor, Suite 7240, New York, NY, USA, 10118

Website

https://www.hookipapharma.com

HOOKIPA Pharma Inc is a clinical stage biopharmaceutical company developing a class of immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform that is designed to reprogram the body's immune system. It uses off-the-shelf technologies, VaxWave and TheraT, to elicit directly within patients a response of antigen-specific killer T cells and antibodies.

Executives

Reinhard Kandera	director, officer: Chief Financial Officer	C/O HOOKIPA PHARMA INC., 430 EAST 29TH ST., 14TH FLOOR, NEW YORK NY 10016
Jorn Aldag	director, officer: Chief Executive Officer	C/O UNUM THERAPEUTICS INC., 200 CAMBRIDGE PARK DRIVE SUITE 3100, CAMBRIDGE MA 02210
Mary Theresa Coelho	director	52 SUNRISE PARK ROAD, NEW HAMPTON NY 43017
Katia Schlienger	officer: Chief Medical Officer	350 FIFTH AVENUE, 72ND FLOOR, SUITE 7240, NEW YORK NY 10118
Malte Peters	director	TANGO THERAPEUTICS, INC., 100 BINNEY STREET, UNIT 700, CAMBRIDGE MA 02142
Timothy P. Reilly	director	C/O HOOKIPA PHARMA INC., 350 FIFTH AVENUE, 72ND FLOOR, SUITE 7240, NEW YORK NY 10018
Gilead Sciences Inc	10 percent owner	333 LAKESIDE DR, FOSTER CITY CA 94404
Igor Matushansky	officer: Chief Medical Officer	C/O HOOKIPA PHARMA INC., 430 EAST 29TH STREET, NEW YORK NY 10016
Sofinnova Capital Vi Fcpr	10 percent owner	C/O SOFINNOVA PARTNERS, 17 RUE DE SURENE, PARIS XX 75008
Christine D. Baker	officer: Chief Business Officer	C/O HOOKIPA PHARMA INC., 350 FIFTH AVENUE, 72ND FLOOR, SUITE 7240, NEW YORK NY 10118
Jean-charles Soria	director	C/O HOOKIPA PHARMA INC., 350 FIFTH AVENUE SUITE 7240, NEW YORK NY 10118
Anders Lilja	officer: Sr. VP, Technical Development	C/O HOOKIPA PHARMA INC., 430 EAST 29TH ST., 14TH FLOOR, NEW YORK NY 10016
Klaus Orlinger	officer: Sr. VP, Research	C/O HOOKIPA PHARMA INC., 430 EAST 29TH STREET, 14TH FLOOR, NEW YORK NY 10016
Roman Necina	officer: Chief Technology Officer	C/O HOOKIPA PHARMA INC., 350 FIFTH AVENUE, 72ND FLOOR, SUITE 7240, NEW YORK NY 10118
Forbion Capital Fund Ii Cooperatief U.a.	10 percent owner	C/O HOOKIPA PHARMA INC., 430 EAST 29TH STREET, 14TH FLOOR, NEW YORK NY 10016